Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.